Precision BioSciences, Inc.
DTIL
$4.71
$0.020.43%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -90.93% | -95.61% | 152.15% | 100.27% | -33.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.93% | -95.61% | 152.15% | 100.27% | -33.59% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -90.93% | -95.61% | 152.15% | 100.27% | -33.59% |
| SG&A Expenses | 16.21% | -8.49% | -13.12% | -22.92% | -35.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.22% | -14.25% | 12.37% | -1.64% | -3.43% |
| Operating Income | -66.86% | -72.09% | 871.68% | 68.65% | -22.97% |
| Income Before Tax | -32.09% | -35.63% | 1,179.76% | 161.56% | 30.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.09% | -35.63% | 1,179.76% | 161.56% | 30.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 68.49% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.94% | -103.30% | 375.41% | 134.27% | 42.82% |
| EBIT | -66.86% | -72.09% | 871.68% | 68.65% | -22.97% |
| EBITDA | -79.21% | -91.38% | 2,268.21% | 73.30% | -34.11% |
| EPS Basic | 45.41% | -7.10% | 250.34% | 125.12% | 47.24% |
| Normalized Basic EPS | 42.35% | 27.90% | 679.07% | 148.15% | -68.33% |
| EPS Diluted | 45.35% | -7.10% | 249.24% | 125.12% | 47.27% |
| Normalized Diluted EPS | 42.35% | 27.90% | 675.35% | 148.13% | -68.33% |
| Average Basic Shares Outstanding | 108.24% | 89.83% | 83.18% | 36.42% | 3.86% |
| Average Diluted Shares Outstanding | 108.24% | 89.83% | 84.37% | 36.48% | 3.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
